

Dr. Carrie Marquette  
Assistant Professor, Urology

#### Education

University of Wisconsin	Undergraduate	May 2003	Biology
University of Wisconsin	Doctor of Medicine	May 2007	Medical
University of Alabama	Residency	May 2010	Internal Medicine
University of Alabama	Fellowship	June 2023	Hematology and Oncology

Dr. Carrie Marquette is an Assistant Professor of Urology with LSU Health New Orleans. Her research areas include prostate, bladder, kidney, and testicular cancers. She is an active treating Physician in the Gulf South NCORP for GU Trials in coordination with LSU's Urologic Oncology/Department of Urology and Radiation Oncology at East Jefferson General Hospital in Metairie, LA. Dr. Marquette was also the Division Chief of Medical Oncology with East Jefferson General Hospital.

#### RESEARCH

##### PROSTATE

EA8153 Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial  
2018 – Present

##### UROTHELIAL

EA8192 A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy  
2021 – Present

EA8185 Phase II Study of Bladder-Sparing Chemoradiation with Durvalumab in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)  
2020 – Present

SWOG 1806 Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.  
2019 – Present

CITN-14 A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients with Locally Advanced or Metastatic Urothelial Carcinoma  
2019 – 2022

ALLIANCE A031501 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation  
2018 – Present

ALLIANCE A031701 A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations  
2018 – Present

SWOG 1605: Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer  
2017 – 2019

RENAL  
NRG GU012 Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)  
2022– Present

SWOG 1931 Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)  
2020 – Present

ALLIANCE A031704 PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated RENal Cell CancEr [PDIGREE]  
2020 – Present

ALLIANCE A031701 A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)  
2020 – Present

EA 8143 A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)  
2017 – Present